This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Performing ETFs of the Third Quarter
by Neena Mishra
Healthcare emerged as the new leader in Q3. Here is what investors need to know about best performing sectors and ETFs.
J&J's Phase III Data Shows Switch to its HIV Drug Beneficial
by Zacks Equity Research
Data from the 96-week long phase III EMERALD study shows that switching to J&J's (JNJ) Symtuza maintains high virologic suppression.
Here's Why J&J (JNJ) is a Good Bet in a Troubled Market
by Zacks Equity Research
A diversified portfolio, robust pipeline, strong growth of new drugs and a consistent dividend payout make Johnson & Johnson (JNJ) a good bet amid market turmoil as well as over the long term.
Novartis, Boston Pharma Ink Deal for 3 Anti-Infective Drugs
by Zacks Equity Research
Novartis inks licensing deal with Boston Pharma for the development of three novel anti-infective drug candidates.
Merck & Other Pharma Players Await FDA Decisions in October
by Kinjel Shah
FDA grants approval to 41 new treatments till the end of September.
Are You Looking for a High-Growth Dividend Stock? Johnson & Johnson (JNJ) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Healthcare ETF (IYH) Hits New 52-Week High
by Sweta Killa
This healthcare ETF hits a new 52-week high. Are more gains in store for this ETF?
Johnson & Johnson (JNJ) Stock Moves -0.04%: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $138.17, moving -0.04% from the previous trading session.
Women Health a Prime Concern Worldwide: 3 Stocks in Focus
by Zacks Equity Research
Women health care gradually gaining importance globally, investors might keep an eye on a few stocks.
Geron's Stock Plunges as J&J Ends Imetelstat Collaboration
by Zacks Equity Research
Geron (GERN) announces termination of collaboration with J&J for development of its sole pipeline candidate, imetelstat.
Allergan Eyes Vraylar Label Expansion, FDA Accepts sNDA
by Zacks Equity Research
FDA accepts Allergan's (AGN) sNDA for label expansion of its schizophrenia drug, Vraylar (cariprazine) to include treatment of bipolar depression.
Glaxo's Tuberculosis Vaccine Positive in Mid-Stage Study
by Zacks Equity Research
Glaxo's (GSK) vaccine candidate, M72/AS01E, achieves significant reduction in incidence of pulmonary tuberculosis in HIV-negative patients with latent tuberculosis infection.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Visa, Verizon, Alphabet and Altria
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Visa, Verizon, Alphabet and Altria
Bull of the Day: Penumbra (PEN)
by Kevin Cook
Innovation in stroke treatment with catheter-based technologies has launched a new rocket of med-tech
Top Research Reports for Johnson & Johnson, Visa & Verizon
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Visa (V) and Verizon (VZ).
J&J's Esketamine Fails to Meet Endpoint in Phase III Study
by Zacks Equity Research
J&J's (JNJ) late-stage candidate, esketamine nasal spray, fails to show statistical significance for the primary endpoint in a phase III study on patients with treatment-resistant depression.
AstraZeneca's Diabetes Treatment Reduces Cardiovascular Risk
by Zacks Equity Research
AstraZeneca's (AZN) Farxiga led to a statistical significant reduction in hospitalization for heart failure or CV death in a cardiovascular outcomes study.
J&J Files NDA for Erdafitinib in Urothelial Cancer Indication
by Zacks Equity Research
Johnson & Johnson (JNJ) submits regulatory application to the FDA seeking approval of pan-FGFR inhibitor, erdafitinib, for the treatment of metastatic urothelial cancer, a type of bladder cancer.
Aduro's Cancer Arm & Strong Collaborations Boost Growth
by Zacks Equity Research
Aduro focuses on a broad pipeline of novel immunotherapies, developed for treating various types of cancers. Its collaboration agreements with large pharma companies fetch in regular funds.
Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV
by Zacks Equity Research
Glaxo (GSK) submits a regulatory application in the EU for a single-tablet, two-drug regimen of dolutegravir and lamivudine for the first-line treatment of HIV-1 infection.
Pfizer's Skin Disease Candidates Positive in Mid-Stage Study
by Zacks Equity Research
Pfizer's (PFE) JAK inhibitor candidates -- PF-06651600 and PF-06700841 -- demonstrate improvements in moderate to severe alopecia areata patients in a phase II study.
Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again
by Zacks Equity Research
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Is Artificial Intelligence the Next Big Thing in Biotech?
by Kinjel Shah
Artificial intelligence can drastically reduce the time taken to develop new life-saving drugs.
Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus
by Zacks Equity Research
Label expansion of Merck's (MRK) Keytruda and FDA approval of AstraZeneca's (AZN) leukemia drug grab headlines this week
Pharma/Biotech Stocks to Watch This Prostate Cancer Month
by Zacks Equity Research
Here we highlight a few companies that are focused on developing treatments for prostate cancer.